A Phase 3 interventional study of Denosumab in Cancer, Carcinoma and Castrate-Resistant Prostate Cancer, sponsored by Amgen. Completed at 74 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-18.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to describe the safety and tolerability of up to 5 years (ie, 3 years under the 20040138 Amgen study and 2 years on this study) denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab for non-metastatic prostate cancer.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 384 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Denosumab
60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
Overall Survival Through Month 24
Time frame: 24 months
First subject enrollment date: 18 February 2009; Last subject enrollment date: 11 May 2010
| Milestone | Placebo/Denosumab 60 mg SC Q6M | Denosumab/Denosumab 60 mg SC Q6M |
|---|---|---|
| Started | 186 | 198 |
| Completed | 144 | 145 |
| Not completed | 42 | 53 |
| Withdrew: Investigator decision, or other reasons | 2 | 3 |
| Withdrew: Noncompliance | 0 | 1 |
| Withdrew: Administrative decision | 1 | 2 |
| Withdrew: Disease progression | 3 | 3 |
| Withdrew: Consent withdrawn | 16 | 19 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Adverse event | 5 | 9 |
| Withdrew: Death | 11 | 13 |
| Participants | Placebo/Denosumab 60 mg SC Q6M | Denosumab/Denosumab 60 mg SC Q6M |
|---|---|---|
| Overall Survival Through Month 24 | 174 | 184 |
Collected over about 38 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/ Denosumab 60 mg Q6M | — | 45/185 (24.3%) | 47/185 (25.4%) |
| Denosumab/ Denosumab 60 mg Q6M | — | 51/199 (25.6%) | 46/199 (23.1%) |
| Event | Placebo/ Denosumab 60 mg Q6M | Denosumab/ Denosumab 60 mg Q6M |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 5/185 | 0/199 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/185 | 2/199 |
| Cerebrovascular accidentNervous system disorders | 3/185 | 2/199 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/185 | 0/199 |
| HaematuriaRenal and urinary disorders | 1/185 | 3/199 |
| AnaemiaBlood and lymphatic system disorders | 2/185 | 2/199 |
| CellulitisInfections and infestations | 2/185 | 1/199 |
| Clostridium difficile colitisInfections and infestations | 2/185 | 1/199 |
| PneumoniaInfections and infestations | 2/185 | 2/199 |
| DehydrationMetabolism and nutrition disorders | 2/185 | 0/199 |
| Event | Placebo/ Denosumab 60 mg Q6M | Denosumab/ Denosumab 60 mg Q6M |
|---|---|---|
| ConstipationGastrointestinal disorders | 16/185 | 13/199 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/185 | 10/199 |
| Urinary tract infectionInfections and infestations | 6/185 | 12/199 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 11/185 | 9/199 |
| NauseaGastrointestinal disorders | 8/185 | 11/199 |
| Back painMusculoskeletal and connective tissue disorders | 8/185 | 11/199 |
| Age, Continuous(Years) | Placebo/Denosumab 60 mg SC Q6M | Denosumab/Denosumab 60 mg SC Q6M | Total |
|---|---|---|---|
| Mean | 73 ± 7.1 | 74.1 ± 6.6 | 73.6 ± 6.9 |
| Sex: Female, Male(Participants) | Placebo/Denosumab 60 mg SC Q6M | Denosumab/Denosumab 60 mg SC Q6M | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 186 | 198 | 384 |
| Race/Ethnicity, Customized(Participants) | Placebo/Denosumab 60 mg SC Q6M | Denosumab/Denosumab 60 mg SC Q6M | Total |
|---|---|---|---|
| White or Caucasian | 153 | 173 | 326 |
| Black or African American | 6 | 8 | 14 |
| Hispanic or Latino | 26 | 17 | 43 |
| Japanese | 1 | 0 | 1 |
Ran from Feb 2009 to primary completion in May 2012, 39 months.
Results were first posted in Sep 2013, 1 year 4 months after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 39 months is below that.
Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab